Figure 1.
Correlation between baseline (D0) antibody levels and 6 months after vaccination (D3). Blue rings present individual results; red line – 95% confidence interval (CI)
Table 1.
Correlation between baseline (D0) antibody levels and further sampling (D1 - after 1st dose - up to 7 days before the second dose, D2 – 1 month after vaccination, D3 – 6 months after vaccination)
| Antibody levels | Spearman rank correlation | ||
|---|---|---|---|
| N | R Spearman | p | |
| D0 & D1 | 87 | 0.73 | 0.000 |
| D0 & D2 | 87 | 0.34 | 0.001 |
| D0 & D3 | 87 | 0.45 | 0.000 |
Figure 2.
Initial antibody level for groups A (COVID-19 convalescents with increase of antibody level after 2nd dose) and C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose) and BMI level. Blue rings present individual results; red line – 95% confidence interval (CI)
Figure 3.
Antibody levels 6 months after vaccination (D3) for group A (COVID-19 convalescents with increase of antibody level after 2nd dose), B (naïve patients) and C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose). Whiskers drawn from minimum (min) to maximum (max).
Table 2.
Minimal (min), maximal (max), median (Me), IQR (Interquartile range), SD (standard deviation) and mean results [IU/ml] on following stages of the study. A (COVID-19 convalescents with increase of antibody level after 2nd dose) – 27 patients, B (naïve patients) - 30, C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose). - 30; 87 participants in total. P-value was find using Kruskal-Wallis test
| group | Mean [IU/mL] | SD [IU/mL] | Min-max [IU/mL] | Me [IQR] [IU/mL] | P | |
|---|---|---|---|---|---|---|
| D0 | A | 162.4 | 182.8 | 0.0–896.0 | 92.8 [44.2–227.7] | 0.000 |
| C | 222.0 | 289.5 | 0.0–1344.0 | 128.1 [83.2–268.8] | ||
| B | 0.000 | 0.000 | 0.0–0.0 | 0.000 [0–0] | ||
| total | 127.0 | 218.0 | 0.0–1344.0 | 57.6 [0.0–144.5] | ||
| D1 | A | 5959.5 | 2415.7 | 1830.4–11392.0 | 5587.2 [4480.0–7680.0] | 0.000 |
| C | 7638.5 | 5390.0 | 1968.0–21800.0 | 5472.0 [4000.0–8256.0] | ||
| B | 856.0 | 875.1 | 185.6–3088.0 | 536.0 [320.0–889.6] | ||
| total | 4778.6 | 4525.2 | 185.6–21800.0 | 4000.0 [777.9–6075.0] | ||
| D2 | A | 7664.4 | 2616.5 | 3360.0–14360.0 | 7520.0 [4992.0–9280.0] | 0.000 |
| C | 5547.2 | 3845.9 | 1129.0–19840.0 | 4608.0 [3120.0–7456.0] | ||
| B | 4451.9 | 1569.1 | 1664.0–7680.0 | 4032.0 [3360.0–5440.0] | ||
| total | 5826.6 | 3103.9 | 1129.0–19840.0 | 4832.0 [3456.0–7536.0] | ||
| D3 | A | 2417.1 | 1480.2 | 344.0–7316.0 | 2336.0 [1453.0–3096.0] | 0.000 |
| C | 2146.4 | 2453.0 | 236.0–12099.0 | 1462.5 [819.0–2177.0] | ||
| B | 965.4 | 485.8 | 340.0–2650.0 | 819.0 [609.0–1216.0] | ||
| total | 1823.2 | 1781.8 | 236.0–12099.0 | 1301.0 [806.0–2336.0] |
Table 3.
Delta (difference) between antibody levels 1 month after vaccination (D2) and 6 months after vaccination (D3); minimal (min), maximal (max), median (Me), IQR, SD (standard deviation), N – number of subjects, total – summary number of participants. P-value was find using Kruskal-Wallis test
| group | Mean [IU/mL] | N | SD [IU/mL] | Min-max [IU/mL] | Me [IQR] [IU/mL] | p |
|---|---|---|---|---|---|---|
| A | 5247.2 | 27 | 2566.4 | 1383.0–13459.0 | 5389.0 [3354.0–7134.0] | 0.003 |
| C | 3400.8 | 30 | 1811.0 | 756.0–7741.0 | 3158.5 [2024.0–5012.0] | |
| B | 3486.5 | 30 | 1461.3 | 614.0–6331.0 | 3105.0 [2654.0–4538.0] | |
| total | 4003.4 | 87 | 2126.7 | 614.0–13459.0 | 3505.0 [2496.0–5535.0] |
Figure 4.
Delta (difference) between antibody levels 1 month after vaccination (D2) and 6 months after vaccination (D3)